ArticleFrontiers in public health2025
Inflammation mediation of the association between brominated flame retardants and psoriasis among U.S. adults.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Brominated flame retardants (BFRs), widely applied in fire prevention, are persistent environmental pollutants. Accumulating evidence indicates that BFRs can trigger inflammatory responses in humans, potentially contributing to various diseases. Given the central role of inflammation in psoriasis pathogenesis, investigating the association between BFR exposure and psoriasis risk is of considerable importance. Methods: We analyzed data from the 2005-2006 and 2009-2014 cycles of the National Health and Nutrition Examination Survey (NHANES). concentrations of BFRs were natural logarithmic transformed and categorized into quartiles. The association between BFR exposure and psoriasis was evaluated using multivariable regression models, restricted cubic spline analysis, mediation analysis, and interaction testing to assess both individual and combined effects. Results: Among 4,251 adult participants, 123 (2.9%) reported having psoriasis. After adjusting for covariates, individuals in the highest quartile of polybrominated diphenyl ether 153 (PBDE153) exposure (Q4) exhibited a significantly increased risk of psoriasis compared to those in the lowest quartile (Q1) (OR = 2.89, 95% CI: 1.26-6.61, Conclusion: This study suggests a positive association between PBDE153 exposure and psoriasis risk, with inflammatory pathways playing a partial mediating role. However, the cross-sectional design precludes causal inference. Therefore, longitudinal studies and experimental research are needed to establish such causal relationships.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.